This paper assesses the value of take-home Alzheimer’s dementia (AD) treatments over physician-administered ones. We find that shifting from a physician-administered treatment to a home-based one in the US would generate a value of $4.67 billion to $25.51 billion annually. Of this overall value, 32.05% to 50.28% would accrue to patients and caregivers and 44.75% -61.16% to private or public payers that may thus result in lower premiums or taxes.
To read the full paper, click here.